MCID: MTR007
MIFTS: 39

Motor Peripheral Neuropathy

Categories: Muscle diseases, Neuronal diseases

Aliases & Classifications for Motor Peripheral Neuropathy

MalaCards integrated aliases for Motor Peripheral Neuropathy:

Name: Motor Peripheral Neuropathy 12 14
Peripheral Motor Neuropathy 12 69
Motor Neuritis 12 14
Hereditary Motor and Sensory Neuropathies 69
Hereditary Motor and Sensory Neuropathy 12
Hereditary Sensory and Motor Neuropathy 41
Neuropathic Muscular Atrophy 12
Hsmn 12

Classifications:



Summaries for Motor Peripheral Neuropathy

MalaCards based summary : Motor Peripheral Neuropathy, also known as peripheral motor neuropathy, is related to charcot-marie-tooth disease, axonal, type 2a1 and charcot-marie-tooth disease, x-linked dominant, 1, and has symptoms including neurologic symptoms An important gene associated with Motor Peripheral Neuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Lidocaine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and liver, and related phenotypes are behavior/neurological and cellular

Related Diseases for Motor Peripheral Neuropathy

Diseases related to Motor Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2a1 33.0 KIF1B MFN2
2 charcot-marie-tooth disease, x-linked dominant, 1 32.9 GJB1 MPZ
3 charcot-marie-tooth disease, axonal, type 2b 32.5 GJB1 KIF1B MPZ PMP22
4 charcot-marie-tooth disease, demyelinating, type 1b 32.1 GJB1 KIF1B MPZ MTMR2 PMP22
5 hypertrophic neuropathy of dejerine-sottas 32.1 GJB1 KIF1B MPZ MTMR2 PMP22
6 charcot-marie-tooth disease, type 4d 32.0 GJB1 MFN2 NDRG1
7 charcot-marie-tooth neuropathy type 1 31.9 GJB1 MPZ PMP22
8 charcot-marie-tooth disease type 2a 31.7 KIF1B MFN2
9 hereditary motor and sensory neuropathy, type iic 31.7 GJB1 KIF1B MFN2 MPZ NDRG1 TFG
10 roussy-levy hereditary areflexic dystasia 31.5 KIF1B MFN2 MPZ PMP22
11 neuropathy, hereditary, with liability to pressure palsies 31.4 GJB1 KIF1B MFN2 MPZ PMP22
12 charcot-marie-tooth disease, demyelinating, type 1a 31.4 GJB1 KIF1B MFN2 MPZ MTMR2 PMP22
13 charcot-marie-tooth disease and deafness 31.0 GJB1 KIF1B MFN2 MPZ MTMR2 PMP22
14 charcot-marie-tooth disease, demyelinating, type 1d 30.7 GJB1 KIF1B MPZ MTMR2 NDRG1 PMP22
15 charcot-marie-tooth disease 30.4 GJB1 KIF1B MFN2 MPZ MTMR2 NDRG1
16 charcot-marie-tooth disease, demyelinating, type 1c 30.3 GJB1 KIF1B MPZ MTMR2 NDRG1 PMP22
17 hereditary neuropathies 29.8 GJB1 MFN2 MPZ MTMR2 NDRG1 PMP22
18 charcot-marie-tooth disease, axonal, type 2e 29.6 GJB1 KIF1B MFN2 MPZ MTMR2 NDRG1
19 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 29.5 DCAF8 GJB1 KIF1B MFN2 MPZ MTMR2
20 neuritis 29.3 MPZ PMP22
21 neuropathy 28.4 GJB1 MFN2 MPZ PMP22 SLC12A6 TFG
22 hereditary motor and sensory neuropathy v 12.7
23 hereditary motor and sensory neuropathy with acrodystrophy 12.4
24 neuropathy, hereditary motor and sensory, russe type 12.3
25 gdap1-related hereditary motor and sensory neuropathy 12.2
26 neuropathy, hereditary motor and sensory, type via 12.2
27 charcot-marie-tooth disease, axonal, autosomal dominant, type 2a2a 12.1
28 agenesis of the corpus callosum with peripheral neuropathy 12.1
29 neuropathy, hereditary motor and sensory, okinawa type 12.0
30 neuropathy, hereditary motor and sensory, type vib 11.7
31 refsum disease, classic 11.5
32 neuropathy, hereditary motor and sensory, with deafness, mental retardation, and absent sensory large myelinated fibers 11.5
33 giant axonal neuropathy 2, autosomal dominant 11.5
34 charcot-marie-tooth disease, axonal, type 2t 11.5
35 charcot-marie-tooth disease type 2a2 11.5
36 charcot-marie-tooth disease, type 4b2 11.4
37 charcot-marie-tooth disease, axonal, type 2b1 11.4
38 charcot-marie-tooth disease, axonal, type 2b2 11.4
39 x-linked charcot-marie-tooth disease 11.3
40 neuropathy, hereditary sensory and autonomic, type iia 11.2
41 charcot-marie-tooth disease type 5 11.2
42 autosomal dominant charcot-marie-tooth disease type 2 with giant axons 11.2
43 charcot-marie-tooth disease type 2c 11.2
44 pmp2-related charcot-marie-tooth disease type 1 11.2
45 motor neuropathy, peripheral, with dysautonomia 11.1
46 intermittent claudication 11.1
47 hereditary neuropathy with liability to pressure palsy 10.3 MPZ PMP22
48 brachial plexus neuropathy 10.3 KIF1B PMP22
49 foot drop 10.2 MPZ PMP22
50 charcot-marie-tooth disease, axonal, type 2i 10.2 KIF1B MPZ

Graphical network of the top 20 diseases related to Motor Peripheral Neuropathy:



Diseases related to Motor Peripheral Neuropathy

Symptoms & Phenotypes for Motor Peripheral Neuropathy

UMLS symptoms related to Motor Peripheral Neuropathy:


neurologic symptoms

MGI Mouse Phenotypes related to Motor Peripheral Neuropathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 PMP22 SLC12A6 TARDBP GJB1 KIF1B MFN2
2 cellular MP:0005384 9.87 GJB1 MFN2 MPZ NDRG1 PMP22 SLC12A6
3 growth/size/body region MP:0005378 9.86 GJB1 KIF1B MFN2 MTMR2 NDRG1 PMP22
4 mortality/aging MP:0010768 9.76 MFN2 MPZ MTMR2 NDRG1 PMP22 TARDBP
5 muscle MP:0005369 9.43 KIF1B MFN2 NDRG1 PMP22 SLC12A6 TARDBP
6 nervous system MP:0003631 9.28 GJB1 KIF1B MFN2 MPZ MTMR2 NDRG1

Drugs & Therapeutics for Motor Peripheral Neuropathy

Drugs for Motor Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Donepezil Approved Phase 4 120014-06-4 3152
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
8 Antioxidants Phase 4,Phase 2,Phase 3
9 Protective Agents Phase 4,Phase 2,Phase 3
10 Analgesics Phase 4,Phase 3,Phase 2
11 Calcium, Dietary Phase 4,Phase 2
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
13 Anti-Inflammatory Agents Phase 4,Phase 2
14 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
15 Thioctic Acid Phase 4,Phase 2
16 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
17 Vitamin B Complex Phase 4,Phase 2,Phase 3
18 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
19 Anti-Anxiety Agents Phase 4,Phase 2
20 Anticonvulsants Phase 4,Phase 2
21 Antidepressive Agents Phase 4,Phase 3
22 calcium channel blockers Phase 4,Phase 2
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
24 Cholinergic Agents Phase 4,Phase 2,Phase 3
25 Excitatory Amino Acid Antagonists Phase 4,Phase 3
26 Excitatory Amino Acids Phase 4,Phase 3
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
28 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
29 Nootropic Agents Phase 4,Phase 2,Phase 3
30 Psychotropic Drugs Phase 4,Phase 3,Phase 2
31 Tranquilizing Agents Phase 4,Phase 3,Phase 2
32 Anesthetics Phase 4,Phase 3
33 Anti-Arrhythmia Agents Phase 4,Phase 2
34 Diuretics, Potassium Sparing Phase 4,Phase 2
35 Sodium Channel Blockers Phase 4,Phase 2
36 Hormone Antagonists Phase 4,Phase 2,Phase 3
37 Hormones Phase 4,Phase 2,Phase 3
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
39 Immunosuppressive Agents Phase 4,Phase 2
40 Antimanic Agents Phase 4
41 Antiparkinson Agents Phase 4
42 Cholinesterase Inhibitors Phase 4
43 Dopamine Agents Phase 4
44 Duloxetine Hydrochloride Phase 4
45 GABA Agents Phase 4
46
Serotonin Phase 4 50-67-9 5202
47 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
48 Alpha-lipoic Acid Nutraceutical Phase 4,Phase 2
49 Folate Nutraceutical Phase 4,Phase 2,Phase 3
50 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 88)

# Name Status NCT ID Phase Drugs
1 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
2 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
3 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
4 Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Unknown status NCT01289704 Phase 2, Phase 3
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. Completed NCT01827072 Phase 3 NPB-01
6 Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy Completed NCT00666263 Phase 3
7 LIME Study (LFB IVIg MMN Efficacy Study) Completed NCT01951924 Phase 3 Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
8 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
9 High Dose Ascorbic Acid Treatment of CMT1A Completed NCT00484510 Phase 2, Phase 3 Ascorbic acid (Vitamin C);placebo
10 Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome Completed NCT02141035 Phase 2, Phase 3 Acetyl-l-carnitine;placebo
11 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
12 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
13 Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Recruiting NCT03023540 Phase 3 PXT3003
14 Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity Recruiting NCT03013543 Phase 2, Phase 3 Setmelanotide
15 Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) Active, not recruiting NCT02579759 Phase 3 PXT3003 dose 1;PXT3003 dose 2;placebo
16 Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome Not yet recruiting NCT03184584 Phase 2, Phase 3 PBI-4050
17 Erythropoietin Spinal Cord Compression Randomized Trial Terminated NCT00220675 Phase 2, Phase 3 Erythropoietin infusion
18 Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome Unknown status NCT02739217 Phase 2 PBI-4050
19 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Unknown status NCT02314208 Phase 2 Xenbilox;Tahor
20 Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy Completed NCT00268788 Phase 2 Subcutaneous immunoglobulin;Intravenous immunoglobulin
21 A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN) Completed NCT00701662 Phase 2
22 Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy Completed NCT00041795 Phase 2 leteprinim potassium (Neotrofin)
23 Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
24 A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
25 Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Completed NCT01171859 Phase 2 Doxycycline + Tauroursodeoxycholic acid
26 The Treatment of the Median Nerve for the Elimination of the Symptoms Associated With the Carpal Tunnel Syndrome Completed NCT00634738 Phase 1, Phase 2
27 Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease Completed NCT00541164 Phase 1, Phase 2 Coenzyme Q10
28 Ascorbic Acid Treatment in CMT1A Trial (AATIC) Completed NCT00271635 Phase 2 Placebo;ascorbic acid
29 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
30 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease Completed NCT02561702 Phase 2 Mexiletine
31 A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. Recruiting NCT03254199 Phase 2 FLX-787-ODT (orally disintegrating tablet);Placebo ODT
32 Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A Recruiting NCT02600286 Phase 2 EllaOne;EllaOne placebo
33 Influence of Pronator Teres Release on Treatment of Median Nerve Compression Neuropathy Recruiting NCT01562860 Phase 2
34 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Recruiting NCT03124459 Phase 2 ACE-083
35 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
36 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2 IMD Preparative Regimen;Osteopetrosis Only Preparative Regimen;Osteopetrosis Haploidentical Only Preparative Regimen;cALD SR-A (Standard-Risk, Regimen A);cALD SR-B (Standard-Risk, Regimen B);cALD HR-D (High-Risk, Regimen C);cALD HR-D (High-Risk, Regimen D)
37 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx Active, not recruiting NCT01088802 Phase 2 Cisplatin;Carboplatin
38 Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) Enrolling by invitation NCT02556437 Phase 2 HyQvia;Subcuvia
39 Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy Recruiting NCT02362438 Phase 1 Intrathecal Delivery of scAAV9/JeT-GAN
40 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
41 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
42 Functional Electrical Stimulation in Chronic Kidney Disease Unknown status NCT02336776
43 Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs Unknown status NCT01918826
44 Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A Unknown status NCT01750710
45 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
46 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
47 Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program Completed NCT00716131
48 An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients Completed NCT02429947
49 Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device Completed NCT01753778
50 Survey of Current Management of Orthopaedic Complications in CMT Patients Completed NCT02001038

Search NIH Clinical Center for Motor Peripheral Neuropathy

Cochrane evidence based reviews: hereditary sensory and motor neuropathy

Genetic Tests for Motor Peripheral Neuropathy

Anatomical Context for Motor Peripheral Neuropathy

MalaCards organs/tissues related to Motor Peripheral Neuropathy:

38
Kidney, Testes, Liver, Spinal Cord

Publications for Motor Peripheral Neuropathy

Articles related to Motor Peripheral Neuropathy:

# Title Authors Year
1
Both Schwann cell and axonal defects cause motor peripheral neuropathy in Ebf2-/- mice. ( 21220016 )
2011
2
Paraneoplastic encephalomyelitis/sensory motor peripheral neuropathy - an autopsy case study. ( 16012914 )
2005
3
Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. ( 8565254 )
1995
4
Sensory and motor peripheral neuropathy in olivopontocerebellar atrophy. ( 3014798 )
1986
5
Hereditary motor peripheral neuropathy predominantly affecting the arms. ( 180264 )
1976

Variations for Motor Peripheral Neuropathy

ClinVar genetic disease variations for Motor Peripheral Neuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 DYNC1H1 NM_001376.4(DYNC1H1): c.1792C> T (p.Arg598Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780564 GRCh37 Chromosome 14, 102452354: 102452354

Expression for Motor Peripheral Neuropathy

Search GEO for disease gene expression data for Motor Peripheral Neuropathy.

Pathways for Motor Peripheral Neuropathy

Pathways related to Motor Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 GJB1 MPZ PMP22

GO Terms for Motor Peripheral Neuropathy

Biological processes related to Motor Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelination GO:0042552 8.96 MPZ PMP22
2 chemical synaptic transmission GO:0007268 8.8 MPZ PMP22 SLC12A6

Sources for Motor Peripheral Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....